healthcare News

Apogee Therapeutics surges 19% on positive eczema drug trial data
Healthcare
4d ago

Apogee Therapeutics surges 19% on positive eczema drug trial data

Phase 2 APEX trial shows durable response with less frequent dosing, positioning drug for Phase 3 in second half of 2026

Insmed ARIKAYCE study meets all endpoints despite 5.6% stock decline
Healthcare
4d ago

Insmed ARIKAYCE study meets all endpoints despite 5.6% stock decline

Phase 3b ENCORE trial shows statistically significant improvements in MAC lung disease patients, supporting label expansion to broader patient population

Talphera beats EPS expectations on 50% enrollment milestone
Healthcare
4d ago

Talphera beats EPS expectations on 50% enrollment milestone

Biotech raises 2026 guidance to fund NEPHRO CRRT trial completion as PMA filing looms

Avalo Therapeutics plunges 29% as 2025 loss widens to $78.3M
Healthcare
4d ago

Avalo Therapeutics plunges 29% as 2025 loss widens to $78.3M

Biotech's $50.1M R&D spend for Phase 2 LOTUS trial drives earnings miss ahead of Q2 2026 data catalyst

Bristol Myers Opdivo approval spurs trading volume despite share decline
Healthcare
6d ago

Bristol Myers Opdivo approval spurs trading volume despite share decline

FDA expands flagship cancer drug to untreated Hodgkin lymphoma, potentially adding billions in revenue as institutional investors take positions

Milestone Pharmaceuticals' CARDAMYST launch tests investor patience
Healthcare
1w ago

Milestone Pharmaceuticals' CARDAMYST launch tests investor patience

Commercial execution underway but mounting losses weigh on pre-commercial company as $200M cash runway provides buffer into 2027

Novartis to acquire breast cancer drug SNV4818 for up to $3B
Healthcare
1w ago

Novartis to acquire breast cancer drug SNV4818 for up to $3B

Pan-mutant selective PI3Kα inhibitor targets 40% of HR+/HER2- breast cancer patients with worse prognosis

Alumis shares jump 82% on Phase 3 success for psoriasis drug
Healthcare
1w ago

Alumis shares jump 82% on Phase 3 success for psoriasis drug

Biotech plans FDA submission for ESK-001 in second half of 2026, marking first potential commercial product